查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1265913

全球研究用抗體市場

Research Antibodies
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

研究用抗體的全球市場在2030年前將達到66億美元

在COVID-19後改變的商務環境中，2022年47億美元的研究用抗體的全球市場，2030年之前達到66億美元的規模，在2022年～2030年預計將以年複合成長率4.2％增長。本報告所分析之市場區隔之一的試劑年複合成長率將記錄3.9％，到分析期間結束時將達到54億美元。抗體領域，考慮疫情後的復甦，今後8年的年複合成長率將修正為6.1％。

美國市場估算為14億美元，中國則將以年複合成長率3.8％的速度成長

美國的研究用抗體市場在2022年估算為達到14億美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為3.8％，在2030年達到11億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以4％和2.9％的速度成長。在歐洲市場中，德國以年複合成長率3.1％成長。

調查對像企業範例

  • Abcam plc
  • Active Motif, Inc.
  • Affinity Biologicals, Inc.
  • Agilent Technologies, Inc.
  • BD
  • Beckman Coulter, Inc.
  • Bethyl Laboratories, Inc.
  • Bio SB
  • BioLegend, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Jackson ImmunoResearch Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN
  • Rockland Immunochemicals, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP22701

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Research Antibodies Market to Reach $6.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Research Antibodies estimated at US$4.7 Billion in the year 2022, is projected to reach a revised size of US$6.6 Billion by 2030, growing at aCAGR of 4.2% over the period 2022-2030. Reagent, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$5.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antibodies segment is readjusted to a revised 6.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 3.8% CAGR

The Research Antibodies market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 3.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 2.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Select Competitors (Total 42 Featured) -

  • Abcam plc
  • Active Motif, Inc.
  • Affinity Biologicals, Inc.
  • Agilent Technologies, Inc.
  • BD
  • Beckman Coulter, Inc.
  • Bethyl Laboratories, Inc.
  • Bio SB
  • BioLegend, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Jackson ImmunoResearch Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN
  • Rockland Immunochemicals, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Research Antibodies - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Reagent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Reagent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Western Blotting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Western Blotting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World 8-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World 8-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Immunofluorescence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 22: World 8-Year Perspective for Immunofluorescence by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immunoprecipitation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World 8-Year Perspective for Immunoprecipitation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 27: World Research Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World 8-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 31: World 8-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World 8-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 35: World 8-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Neurobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 37: World 8-Year Perspective for Neurobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 39: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 40: USA Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 41: USA 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 43: USA 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 47: USA 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • CANADA
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Canada 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Canada 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Canada 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • JAPAN
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Japan 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Japan 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Japan 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • CHINA
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 64: China Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 65: China 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 67: China 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 71: China 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • EUROPE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 73: Europe 8-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Europe 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Europe 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • FRANCE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 82: France Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 83: France 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 85: France 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: France 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 89: France 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • GERMANY
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Germany 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 95: Germany 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 97: Germany 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Italy 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 101: Italy 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 103: Italy 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Italy 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • UNITED KINGDOM
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 106: UK Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 107: UK 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 109: UK 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 113: UK 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 131: Rest of World 8-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Sales for Reagent and Antibodies for the Years 2023 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 133: Rest of World 8-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2023 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of World 8-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Sales for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2023 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 137: Rest of World 8-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2023 & 2030

IV. COMPETITION